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Abstract
Background: Hypertension is one of the major causes of disease burden affecting the Finnish population. Over the last decade,
evidence-based care has emerged to complement other approaches to antihypertensive care, often without health economic
assessment of its costs and effects. This study looks at the extent to which changes proposed by the 2002 Finnish evidence-
based Current Care Guidelines concerning the prevention, diagnosis, and treatment of hypertension (the ACCG scenario) can
be considered cost-effective when compared to modelled prior clinical practice (the PCP scenario).
Methods: A decision analytic model compares the ACCG and PCP scenarios using information synthesised from a set of
national registers covering prescription drug reimbursements, morbidity, and mortality with data from two national surveys
concerning health and functional capacity. Statistical methods are used to estimate model parameters from Finnish data. We
model the potential impact of the different treatment strategies under the ACCG and PCP scenarios, such as lifestyle counselling
and drug therapy, for subgroups stratified by age, gender, and blood pressure. The model provides estimates of the differences
in major health-related outcomes in the form of life-years and costs as calculated from a 'public health care system' perspective.
Cost-effectiveness analysis results are presented for subgroups and for the target population as a whole.
Results: The impact of the use of the ACCG scenario in subgroups (aged 40–80) without concomitant cardiovascular and
related diseases is mainly positive. Generally, costs and life-years decrease in unison in the lowest blood pressure group, while
in the highest blood pressure group costs and life-years increase together and in the other groups the ACCG scenario is less
expensive and produces more life-years. When the costs and effects for subgroups are combined using standard decision analytic
aggregation methods, the ACCG scenario is cost-saving and more effective.
Conclusion: The ACCG scenario is likely to reduce costs and increase life-years compared to the PCP scenario in many
subgroups. If the estimated trade-offs between the subgroups in terms of outcomes and costs are acceptable to decision-makers,
then widespread implementation of the ACCG scenario is expected to reduce overall costs and be accompanied by positive
outcomes overall.
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Background
Rationale and objectives of the study
Despite the increasing use of evidence-based guidelines
over the last decade to complement other approaches to
care, there appears to be a relative dearth of English-lan-
guage cost-effectiveness analyses of such guidelines ([1-
11]). There are numerous possible approaches to cost-
effectiveness analysis (CEA) in the field of antihyperten-
sive care (see, e.g., [12-22]), mainly addressing questions
such as 'whom to treat' and 'how to treat'. A literature
database search strategy (see Additional file 1, Table 1)
revealed no CEAs that have been carried out concerning
broad alternative scenarios for antihypertensive care as
outlined in evidence-based guidelines. Therefore, we
undertook a cost-effectiveness analysis to evaluate the rel-
ative impact of the hypothetical application of two scenar-
ios on the costs and effects of the prevention, diagnosis,
and treatment of hypertension in Finland. Based on the
2002 evidence-based Antihypertensive Current Care
Guideline (ACCG) [23], the ACCG scenario is compared
with a prior clinical practice (PCP) scenario. For a descrip-
tion of the development process for the Finnish Current
Care Guidelines see Additional file 2.
The ACCG and PCP scenarios differ in the types of care
they include and, hence, in the clinical outcomes expected
to result from each scenario. We use a combination of
individual-level data (i.e., observed and recorded infor-
mation on a representative population sample of individ-
uals) with data representative of the whole population
(i.e., population data from national registers) to calculate
expected outcomes in each scenario using decision ana-
lytic modelling (see Additional file 3, Figure 1).
The ACCG is aimed primarily at providing health care
professionals with guidance concerning the prevention,
diagnosis, or treatment of hypertension in individuals.
The objective of this cost-effectiveness study is to highlight
some of the opportunity costs of the two scenarios in
undertaking antihypertensive care in the longer term and
at a national level (see Additional file 1, Table 2 for details
of terminology such as opportunity costs). This research is
intended mainly for members of the various bodies and
organisations responsible for the selection and imple-
mentation of publicly funded health care technologies.
Antihypertensive care scenarios
Some important differences between antihypertensive
care according to the 2002 antihypertensive Current Care
guideline and prior clinical practice are shown in Table 1.
The ACCG scenario refers to the hypothetical application
of only part of the ACCG and the PCP scenario refers to
the hypothetical application of observed PCP. These sce-
narios are constructed to form part of a decision analytic
model. The blood pressure groups (BPGs) used in this
study are presented in Table 2. The two scenarios each
involve particular combinations of a variety of therapeutic
interventions, as shown in Table 3.
Base case incremental analysis for both genders, by age group  and blood pressure group Figure 1
Base case incremental analysis for both genders, by age group 
and blood pressure group.
B P G  0B P G  1B P G  2
70–74 €217,000 per life-year €74,000 per life-year ACCG scenario dominates ACCG scenario is d
- €5m - €1m - €5m
-23 life-years -15 life-years 19 life-years -65
65–69 €103,000 per life-year €32,000 per life-year ACCG scenario dominates €7,000 pe
- €6m - €4m - €6m
-56 life-years -110 life-years 312 life-years 395
60–64 €42,000 per life-year €9,000 per life-year ACCG scenario dominates €3,000 pe
- €9m - €8m - €16m
-223 life-years -860 life-years 223 life-years 678
55–59 €15,000 per life-year ACCG scenario dominates ACCG scenario dominates €3,000 pe
- €11m - €3m - €12m
-746 life-years 146 life-years 1,847 life-years 3,420
50–54 €42,000 per life-year ACCG scenario dominates ACCG scenario dominates €5,000 pe
- €24m - €7m - €25m
-572 life-years 1,064 life-years 3,366 life-years 4,476
45–49 €34,000 per life-year ACCG scenario dominates ACCG scenario dominates €10,000 pe
- €29m - €10m - €25m
-841 life-years 1,705 life-years 1,171 life-years 2,040
40–44 €42,000 per life-year ACCG scenario dominates ACCG scenario dominates €6,000 pe
- €38m - €7m - €18m
-904 life-years 891 life-years 287 life-years 1,898
B P G  0B P G  1B P G  2
70–74 ACCG scenario dominates ACCG scenario dominates ACCG scenario dominates €13,000 pe
- €3m - €5m - €11m
4 life-years 15 life-years 332 life-years 567
65–69 €95,000 per life-year €48,000 per life-year €32,000 per life-year €4,000 pe
- €3m - €12m - €12m
-36 life-years -247 life-years -359 life-years 1,327
60–64 €50,000 per life-year €20,000 per life-year ACCG scenario dominates €3,000 pe
- €10m - €14m - €19m
-193 life-years -699 life-years 54 life-years 2,559
55–59 €30,000 per life-year ACCG scenario dominates ACCG scenario dominates €1,000 pe
- €13m - €5m - €24m
-435 life-years 574 life-years 1,387 life-years 12,756
50–54 €42,000 per life-year ACCG scenario dominates €55,000 per life-year €2,000 pe
- €35m - €9m - €29m
-843 life-years 1,404 life-years -527 life-years 7,388
45–49 €69,000 per life-year ACCG scenario dominates €15,000 per life-year €3,000 pe
- €48m - €10m - €28m
-698 life-years 1,892 life-years -1,804 life-years 3,191
40–44 €52,000 per life-year ACCG scenario dominates €45,000 per life-year €4,000 pe
- €60m - €7m - €18m
-1,137 life-years 1,734 life-years -397 life-years 1,812
blood pressure group classification
Table 1: Differences between the two approaches to the 
prevention, diagnosis, and treatment of hypertension.
Clinical practice according to 
the ACCG
Clinical practice prior to the 
publication of the ACCG
prevention prevention
systematic counselling on health-
related lifestyle choices if SBP is 
130–139 mmHg and/or DBP 
85–89 mmHg
a somewhat non-systematic 
approach
diagnosis diagnosis
- BP measurements performed 
according to guideline 
specifications
- variations in BP 
measurement practices
- calculation of CHD risk profiles - other CHD risk factors not 
fully incorporated
treatment treatment
provide lifestyle counselling and 
considered initiation of 
pharmacological therapies with a 
stepwise approach
commonly pharmacological 
therapy, often without lifestyle 
counsellingBMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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The most important assumed differences between the two
scenarios are the following: 1) the frequency and type of
BP measurement, 2) the use of coronary risk assessment,
3) the recommended therapeutic choices – especially –
the preventative role of lifestyle counselling [23]. For
example, in line with the ACCG, diagnostic BP measure-
ment under the ACCG scenario consists of four sets of
duplicate SBP and DBP measurements within a specified
period of time (if the screening SBP is 140 mmHg or more
or the screening DBP is 90 mmHg or more as averaged
over two readings) [24]. In contrast, the PCP scenario is
assumed to include four blood pressure measurements
per year, see Additional file 4, Table 1. The use of coronary
risk assessment tables [25] is advocated in the ACCG and
modelled in the ACCG scenario, but such tables are
assumed not to be used under the PCP scenario. The ther-
apeutic choices for different BP groups under the PCP and
ACCG scenarios differ as shown in Table 3, and the differ-
ences in the pharmacological therapies between the two
scenarios are shown the additional material, see Addi-
tional file 1, Table 3. The lifestyle counselling intervention
is assumed to be applicable to all individuals in the ACCG
scenario, except those in the lowest-numbered BP group,
BPG 0. It is assumed that lifestyle counselling is not used
under the PCP scenario.
The PCP and ACCG scenarios are hypothetically applied
to the individuals in the study population as if antihyper-
tensive care was being initiated. The two scenarios are
applied only to individuals without concomitant cardio-
vascular disease or diabetes. That is, the analysis of the
two scenarios is specific to individuals without diagnoses
of diabetes, coronary heart disease (CHD), or cerebrovas-
cular events (CVEs). In addition, the two scenarios are
restricted to individuals aged 40–74. Almost 1.5 million
Finns, out of a total Finnish population of almost 5.2 mil-
lion, fall into this category. Among this target population
of 1.5 million Finns, over 70% of males and over 60% of
females have elevated blood pressure (SBP exceeding 130
mmHg or DBP over 85 mmHg). The 'do nothing' compa-
rator was assumed not to be a reasonable alternative in the
context of antihypertensive care in a Western European
society.
Methods
Modelling
For the purposes of economic evaluation, a decision
model with Markov cycle sub-trees was built [26]. The
sub-trees consist of 11 Markov states, which describe the
major health-related outcomes and costs associated with
antihypertensive care (see Additional file 3, Figure 3). For
the basic structure of the decision tree see Additional file
3, Figure 3. The Markov cycle duration was set at five years,
the minimum time horizon of the model was 10 years,
and the maximum time horizon was 40 years. Progression
between states is represented by transition probabilities
(see Additional file 1, Table 5). Transitions between states
are determined by the use of both epidemiological study
data and published analyses of clinical trial data. Results
are presented as incremental cost-effectiveness ratios
(ICERs).
To facilitate modelling, the population was divided by
gender and into seven age bands, each five years wide. The
model follows cohorts of individuals (40–44, 45–49, 50–
54, 55–59, 60–64, 65–69, and 70–74) and calculates
costs and outcomes until members of the cohort exceed
Table 3: Main operationalised differences between the PCP and ACCG scenarios.
ACCG scenario Monitoring lifestyle counselling single antihypertensive drug two antihypertensive drugs three antihypertensive drugs
BPG 0 Yes No No No No
BPG 1 No Yes No No No
BPG 2 No Yes Possible* Possible Possible
BPG 3 No Yes Yes Possible Possible
PCP scenario monitoring lifestyle counselling single antihypertensive drug two antihypertensive drugs three antihypertensive drugs
BPG 0 Possible No Possible Possible Possible
BPG 1 Possible No Possible Possible Possible
BPG 2 Possible No Possible Possible Possible
BPG 3 Possible No Possible Possible Possible
* In this table, 'Possible' refers to the potential use of interventions. In the ACCG scenario, this refers to the fact that treatment with 
antihypertensive pharmacological therapy can be considered in this case. For the PCP scenario, data from H2000 suggest that use of 
antihypertensive pharmacological therapy did occur in all BP groups, as did monitoring.
Table 2: Classification of blood pressure: If SBP and DBP fell into 
different groups, the individual was classified in the higher group.
systolic blood pressure 
(in mmHg)
diastolic blood pressure 
(in mmHg)
BPG 0 < 130 and < 85
BPG 1 130–139 and/or 85–89
BPG 2 140–159 and/or 90–99
BPG 3 ≥160 or ≥100BMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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the age of 80. Results are given as incremental cost-effec-
tiveness ratios in 56 age-, gender-, and BP-stratified sub-
groups as well as being aggregated over all subgroups.
A rate of discount of 5% was used for both costs and effec-
tiveness in the base case analysis as well as 0% in sensitiv-
ity analysis in accordance with the guidelines of the
Finnish Ministry of Social Affairs and Health [27]. In addi-
tion, one-way sensitivity analyses were carried out by
changing the probabilities of regimen switching (only
applicable in the ACCG scenario), the distribution of first-
line therapy (only applicable in the ACCG scenario), the
costs of medication, the costs of lifestyle counselling (only
applicable in the ACCG scenario), the costs associated
with morbidity, and the effects of antihypertensive care on
BP. Sensitivity analysis was also carried out by attaching to
the Markov states health-related quality of life (HRQL)
weights as measured by the 15D instrument [28]. For fur-
ther details of the sensitivity analyses, see Additional file
5.
Statistical analysis was carried out using the R statistical
package [29] and version 6.12 of the SAS System [30].
Population data
Data were available from the National Health 2000
Health Examination Survey (H2000), a two-stage strati-
fied cluster sample undertaken in 2000–2001 (which
included 8,028 persons aged 30 years and over and was
representative of all people of that age in Finland) [31].
These data were used to provide prevalence estimates for
BP groups in the population, stratified by age and gender,
as well as a means for calculation of hypothetical treat-
ment effects; an estimate of the use of antihypertensive
medication under PCP; and the proportion of the popula-
tion, stratified by age group and gender, with a risk of
CHD within the next 10 years of ≥ 20% by applying a risk
estimation equation [32]. In addition, the HRQL weights
of the Markov states were derived from these data.
From the entire H2000 dataset, only data on individuals
aged between 40 and 79 were utilised, as the expected
observable frequency of events in other age groups, in
terms of morbidity and mortality, was deemed insuffi-
cient. Further, the dataset was restricted to those individu-
als who have had their BP measured and who have no
history of cardiovascular or related illnesses according to
H2000 study. That is, the sample was restricted to individ-
uals without diagnoses of diabetes, coronary heart disease
(CHD), or cerebrovascular events (CVEs). The resultant
sample size was 3,188. Almost 15% of individuals in this
sample were recorded as using antihypertensive medica-
tion. For these individuals, prior to allocation to one of
the four BP groups, the recorded SBP was increased by 10
Subgroup results on the cost-effectiveness plane Figure 3
Subgroup results on the cost-effectiveness plane.
Table 4: Yearly costs of pharmacological therapies* used in the 
PCP scenario, rounded to the nearest euro, by gender (2001 
prices).
Pharmacological subgroup ATC 
code
male female
hydrochlorothiazide or trichlormethiazide 
and potassium-sparing agents
C03EA 40 42
beta-blocking agents C07A 145 136
combination of metoprolol or bisoprolol 
and thiazides
C07B 141 141
atenolol or metoprolol and other 
antihypertensives
C07F 285 275
calcium channel blockers C08 245 228
ACE inhibitors C09A 203 192
combination of ACE inhibitors and diuretics C09BA 233 228
combination of ACE inhibitors and calcium 
channel blockers
C09BB 349 348
angiotensin II subtype 1 receptor 
antagonists
C09C 251 250
combination of angiotensin II subtype 1 
receptor antagonists and diuretics
C09D 271 274
*(weighted average of the different pharmacological subgroups)
Key for figures 1, 3, and 4 Figure 2
Key for figures 1, 3, and 4.
The ACCG scenario is more effective and less costly than the PCP scenario
The ACCG scenario is less effective and less costly than the PCP scenario
The ACCG scenario is more effective and more costly than the PCP scenario
The ACCG scenario is less effective and more costly than the PCP scenarioBMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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mmHg and DBP by 6 mmHg. The same increase was
applied regardless of BP group (see Additional file 1, Table
6). This simplified adjustment was undertaken because
information for apportioning prior treatment effects more
precisely was not available at the time of this study.
Due to the relatively small sample size in the 70–74 age
group, where necessary, it was assumed that the 75–79 age
group also is representative of the 70–74 age group.
Expansion weights calculated by Statistics Finland for the
H2000 sample were applied to provide estimates of target
population sizes at the national level in the 56 subgroups,
with these subgroups representing approximately 1.5 mil-
lion Finns (i.e., 62% of the Finnish population between
the ages of 40 and 74), of whom almost 720,000 were
male and over 780,000 female. See Additional file 6, Fig-
ures 1, 2, 3.
Transition probabilities and paths of treatment
For modelling purposes, we calculated the transition
probabilities between the Markov states in each of the 28
age- and BP-stratified subgroups for men and women. The
transition probabilities between BP groups are based on
treatment effects (see Additional file 1, Tables 7 and 8)
applied to the individual H2000 data on blood pressure
group membership. The estimated probabilities of mov-
ing from the various BP group states to the states of CHD,
CVEs, and death from those or other causes (i.e., morbid-
ity and fatal event states) are based on the follow-up of the
participants in the Mini-Finland (MF) health examina-
tion/interview survey undertaken between 1978–1980
[33]. Hazard functions were estimated by stratifying the
sample into two age groups, 40–59 and 60–79 (see Addi-
tional file 1, Table 9), due to the relative infrequency of
endpoints in quinquennial age groups. After the first
Markov cycle, the model also allows movements from the
morbidity states to two co-morbidity states: the pertinent
hazard function estimates are shown in (see Additional
file 1, Table 10). All hazard function estimates are trans-
formed into transition probabilities using the formula
P(t) = 1 – exp(-μt) [34]. In the few cases where, due to the
small number of observations in a subgroup, the esti-
mates were not congruent with the work of MacMahon et
al. [35], estimates were smoothed.
The scenarios differ in their treatment paths. Common to
both are the use of mono-, dual-, or triple-drug therapy
and a path defined as monitoring (i.e., without any BP-
modifying treatment). Lifestyle counselling (LSC) is used
only in the ACCG scenario, with or without drug therapy.
The ACCG scenario follows the treatment options pre-
sented in Table 3, such that the type of treatment largely is
determined by BPG. In BPG 0 and BPG 1, monitoring and
LSC are the only options, respectively. In BPG2, all indi-
viduals are assumed to receive LSC and pharmacological
therapy can be considered if the individual's risk of CHD
within the next 10 years is at least 20% [25]. In BPG 3, all
individuals are assumed to receive both LSC and pharma-
cological therapy.
The choice of initial pharmacological therapy in the
ACCG scenario is limited to five alternative monothera-
Table 7: Estimates of the antihypertensive effect of monotherapy 
and combination pharmacological treatment.
Blood pressure level 1 drug 2 drugs 3 drugs
BPG 0 SBP < 130 mmHg and DBP 
< 85 mmHg
5/3 10/6 15/8
BPG 1 SBP 130–139 mmHg and/or 
DBP 85–89 mmHg 
(but not SBP ≥ 140 or DBP 
≥ 90 mmHg)
6/3 12/7 18/10
BPG 2 SBP 140–159 mmHg and/or 
DBP 90–99 mmHg 
(but not SBP ≥ 160 or DBP 
≥ 100 mmHg)
7/4 14/8 21/12
BPG 3 SBP ≥ 160 mmHg or DBP ≥ 
100 mmHg
8/4 16/9 24/13
Table 5: Yearly costs of pharmacological therapies used in the 
ACCG scenario, rounded to the nearest euro, by gender (2001 
prices).
Pharmacological substance ATC code male female
hydrochlorothiazide C03AA03 22 24
bisoprolol C07AB07 112 107
nifedipine C08CA05 243 227
enalapril C09AA02 192 181
candesartan C09CA06 235 237
Table 6: Costs of non-pharmacological treatment-related 
therapies per year*, rounded to the nearest euro, by gender and 
BPG**.
Cost ACCG scenario PCP scenario
BP measurement 15 5
initial diagnostic work-up 38 62
lifestyle counselling 1st year = 36
2nd year = 24
subsequent years = 17
not applicable
follow-up BP measurement Female Male
BPG 0 32 0
BPG 1 10 6 4
BPG 2 27 9 7
BPG 3 57 16 14
* unless otherwise stated
** where applicableBMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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pies: a thiazide diuretic, a calcium channel blocker, a beta
blocker, an ACE inhibitor, or an angiotensin II subtype 1
receptor antagonist. The latter is recommended by the
ACCG when the other drug therapies have resulted in
problematic side effects. In the ACCG scenario, at the start
of the first five-year Markov cycle, there is a possibility of
regimen switching if an individual's hypertension is
poorly controlled or there are side effects. According to the
ACCG, initial therapy is then changed either to another
monotherapy (preferably with a different pharmacologi-
cal effect) or to a combination treatment (especially if the
first drug is a thiazide diuretic or an ACE inhibitor). If
blood pressure still remains poorly controlled, the ACCG
suggests changing one drug in the two-drug combination,
or that adding a third drug with a different effect to the
combination should be considered. The possible alterna-
tives for regimen switching in the ACCG scenario are
shown in Table 8.
The ACCG recommends consideration of costs in the pre-
scription of pharmacological therapies. According to the
ACCG the rational first-line treatment would be thiazides
for 60% of the population (not complicated by other car-
diovascular-related disease) for which drug treatment
would be recommended. In part, this recommendation
was implemented in the base case analysis of our model
by assuming that the majority (60%) of patients receive
thiazide diuretics as their initial treatment. In addition,
from each pharmacological subgroup a relatively inexpen-
sive and widely used pharmacological substance was cho-
sen.
In the PCP scenario there are 24 possible choices of phar-
maceutical monotherapy or pharmaceutical combination
therapies, with no possibility of regimen switching. For
further details on the interventions available in both sce-
narios, see Additional file 1, Table 3.
Estimates of costs
The data used to estimate costs were collated from
national registers, Finnish costing studies [36], an earlier
national study on the costs of antihypertensive care [37],
and an international study of the costs of morbidity asso-
ciated with elevated blood pressure [38].
For the PCP scenario, information on the shares of use of
the pharmacological subgroups of antihypertensive drugs
and their combinations (see Additional file 1, Table 4), as
well as their average costs in 2001, was obtained from the
reimbursement registers of the Finnish Social Insurance
Institution (SII). The SII data include all reimbursements
made under the National Health Insurance Scheme [39].
In calculation of these costs, patients with entitlement to
a special refund on account of concomitant conditions of
diabetes and cardiovascular diseases were excluded.
The costs of pharmacological therapies in the ACCG sce-
nario were estimated on the basis of the ACCG recom-
mendation that from each pharmacological subgroup an
inexpensive and widely used substance should be chosen.
As for the PCP scenario, information on the average costs
of antihypertensive drugs was obtained from the reim-
bursement registers of the SII.
In the base case the substances were valued at their cost to
the health care sector in 2001, excluding value added tax
(VAT). The estimates of yearly costs (including VAT) are
shown in Table 4 and Table 5.
Base case estimates of the non-pharmacological treat-
ment-related costs of prevention, diagnosis, and treat-
ment of hypertension in the ACCG and PCP scenarios are
presented in Table 6. Cost estimates were derived by using
H2000 data; a Finnish lifestyle counselling study [40];
Finnish health care unit costs [36]; and, where necessary,
expert opinion. For further details, see Additional file 4.
Costs applied to the states of CHD, cerebrovascular
events, and combinations of these morbid states were esti-
mated from the related literature [38,41-45] and Finnish
Table 8: Possible regimen changes in the ACCG scenario.
Initial drug 1st additional drug 2nd additional drug
thiazide diuretic ACE inhibitor (or 
angiotensin II subtype 1 
receptor antagonist)
calcium channel 
blocker or beta 
blocker
thiazide diuretic beta blocker ACE inhibitor (or 
angiotensin II subtype 
1 receptor 
antagonist) or 
calcium channel 
blocker
calcium channel 
blocker 
(dihydropyridine 
derivatives)
ACE inhibitor (or 
angiotensin II subtype 1 
receptor antagonist)
thiazide diuretic or 
beta blocker
calcium channel 
blocker
beta blocker ACE inhibitor (or 
angiotensin II subtype 
1 receptor 
antagonist) or 
thiazide diuretic
ACE inhibitor (or 
angiotensin II subtype 
1 receptor antagonist)
thiazide diuretic calcium channel 
blocker or beta 
blocker
ACE inhibitor (or 
angiotensin II subtype 
1 receptor antagonist)
calcium channel blocker thiazide diuretic or 
beta blocker
beta blocker thiazide diuretic ACE inhibitor (or 
angiotensin II subtype 
1 receptor 
antagonist) or 
calcium channel 
blocker
beta blocker calcium channel blocker ACE inhibitor (or 
angiotensin II subtype 
1 receptor 
antagonist) or 
thiazide diureticBMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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health care unit costs [36]. The estimate used for CVEs is
3,000 euros per year and for CHD 1,000 euros per year
[36,38,41-45]. In the combination states of CVE and
CHD, these costs were summed together.
Estimates of effects
The estimated effect of treatment on outcomes is calcu-
lated by first estimating the effect of the expected reduc-
tion in BP on BP group and then by the estimating the
effect of BP group on morbidity and mortality. These esti-
mated effects are then expressed as changes in life-years,
which are calculated on the basis of the cohort's duration
of stay in non-fatal states. Life-years are valued equally in
all BP and morbidity states in the base case analysis and
adjusted for health-related quality of life (HRQL) in a sen-
sitivity analysis. In both the H2000 survey and the MF sur-
vey, the measurement of BP was strictly carried out
according to the World Health Organization (WHO) rec-
ommendations. Antihypertensive effects of treatments are
divided into effects associated with medication, those
associated with lifestyle counselling and those associated
with a combination of the two treatments (see Additional
file 1, Tables 7 and 8). The effectiveness of all pharmaco-
logical therapies (i.e., the change resulting from any par-
ticular pharmacological intervention in terms of change
in BP) is assumed to be the same in the ACCG and PCP
scenarios.
On account of the work of Kastarinen et al. [40], for those
receiving both lifestyle counselling (LSC) and pharmaco-
logical therapy, a reduction due to LSC of 1 mmHg in
both SBP and DBP was assumed in BPG 0, and 2 mmHg
in the other BP groups. In the absence of larger RCTs, LSC
is assumed to decrease SBP by 2.6 mmHg and DBP by 2.7
mmHg for persons not receiving pharmacological treat-
ment [46].
The effect of five-year increases in age on BP as estimated
with regression analysis from the H2000 sample – i.e., the
effect of monitoring (no active treatment but active sur-
veillance) – was similar to that obtained in another study
[47]. These estimates were calculated for two age groups,
40–60 years old and 60–80 years old. In the first of these
groups, SBP was estimated to have increased by 4 mmHg
and DBP by 2 mmHg per five-year period, while in the
60–80-year-old group SBP was estimated to have
increased by 4 mmHg and DBP decreased by 1 mmHg per
five-year period.
The estimates of the antihypertensive effect of pharmaco-
logical monotherapies and combination therapies were
derived from a recent meta-analysis of randomised trials
[48]. According to that study, the five main categories of
blood-pressure-lowering drugs (thiazides, beta blockers,
ACE inhibitors, angiotensin II subtype 1 receptor antago-
nists, and calcium channel blockers) produced similar
reductions in BP. The expected reductions in BP in differ-
ent BP groups under both the ACCG and the PCP scenar-
ios are summarised in Table 7.
It is assumed that the effect of treatments within each sce-
nario on BP group membership occurs only during the
first five-year cycle. In subsequent cycles, transitions
between BP groups result from changes in BP with age
under the assumption that only monitoring would occur
(for estimates of the resource use in terms of monitoring
see Additional file 4, Tables 4, 5 and 6). The Mini-Finland
data [30] were used to help provide estimates of the mor-
bidity and mortality associated with BP group. The MF
data were linked using exact matching of unique identifi-
ers to the Cause of Death Register (Statistics Finland) and
the Hospital Care Register (National Research and Devel-
opment Centre for Welfare and Health). Cox models [32]
were used to produce estimates of hazard functions relat-
ing the BP groups to the morbidity and fatal event states
for the follow-up period of 15 years (see Additional file 1,
Table 9) and estimates of hazard functions relating prior
morbidity to future comorbidity and death (see Addi-
tional file 1, Table 10). For examples of transition proba-
bilities see Additional file 7.
Results
In line with recommendations in the literature (see, e.g.,
[49]), we report analyses in both subgroup and aggregated
form. For the 56 age- and gender-stratified subgroups, the
estimated ICERs and the corresponding numerators and
denominators for the base case analysis are shown (Figure
1). Green cells in Figure 1 (21 in number) show domi-
nance of the ACCG scenario; that is, application of the
ACCG scenario is more effective (produces more life-
years) and is less costly than the PCP scenario. Yellow
shading (12 cells) indicates incremental costs and incre-
mental outcomes, while orange shading (22 cells) indi-
cates decremental costs and decremental outcomes. That
is, the smaller the ICERs with yellow shading or, con-
versely, the larger the ICERs with orange shading, the
more likely the ICERs are to be considered cost-effective.
Red shading (one cell) represents incremental costs and
decremental outcomes (i.e., the PCP scenario dominates).
These results are given for each subgroup over the time
horizon of the study (10 to 40 years, depending on the age
range of the subgroup). See Additional file 1, Table 11 for
the estimated sizes of subgroups. The total target popula-
tion is almost 1.5 million individuals in Finland.
In large part, the subgroup results differ according to
blood pressure group (BPG). Generally, in blood pressure
group 0 (BPG 0, where SBP is below 130 mmHg and DBP
is below 85 mmHg) the effect of the application of the
ACCG scenario was to reduce expected costs at the sameBMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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time as reducing the expected number of life-years.
Largely, for BPG 1 and BPG 2 (where SBP is 130–139
mmHg and/or DBP 85–89 mmHg and SBP is 140–159
mmHg and/or DBP 90–99 mmHg, respectively), the
ACCG scenario was shown to be cost-saving and more
effective (i.e., decreased costs and increased life-years
expected). Generally, in BPG 3 (where SBP is over 160
mmHg or DBP over 100 mmHg), increased expected costs
are associated with an increase in the expected number of
life-years. Figure 3 shows these subgroup results plotted
on the cost-effectiveness plane [50]. We also provide the
approximate size of the Finnish population to which the
results in that quadrant apply (the numbers in brackets in
Figure 3).
As a summary of both Figure 1 and Figure 3, aggregating
the results from the 56 study subgroups indicates that in
comparison to the PCP scenario the use of the ACCG sce-
nario would produce 49,000 extra life-years and save 498
million euros. In this case, the ACCG would be the dom-
inant scenario overall. That is, while the ACCG scenario
should not be classed as cost-effective, it is both cost-sav-
ing and more effective [51].
A cost-effectiveness plane based on the results of one-way
sensitivity analyses (aggregated over all subgroups) of 30
variations of influential variables is shown in Figure 4. For
a detailed presentation of the results of these sensitivity
analyses, see Additional file 5. Almost all aggregated sen-
sitivity analyses showed that the ACCG scenario domi-
nates the PCP scenario – i.e., that the ACCG scenario is
cost-saving and more effective. One exception was the
case where lifestyle counselling was assumed to be four
times more costly than in the base case. In this sensitivity
analysis, with an extreme value used for the cost of life-
style counselling, the aggregated results show that the cost
per life-year saved would be around €8,000.
Despite many thousands of life-years being saved in all
aggregated subgroup analyses, the overall benefit per per-
son is modest. Applying the ACCG scenario would add 12
(six at least, 31 at best) days per person in the target pop-
ulation, although it should be noted that this figure is
averaged over all individuals in the target population of
1.5 million Finns.
Discussion
Over half of Finland's 40–74-year-old 'uncomplicated'
population has elevated blood pressure. The major goal of
the ACCG is to achieve a reduction in blood pressure that
is sufficient for these individuals to lower their risk of car-
diovascular (and related) diseases. As a means to this end,
the ACCG promotes lifestyle modification and rational
use of antihypertensive drugs. The lifestyle counselling
considered to be feasible in the ACCG scenario is by
design a low-intensity patient-counselling programme
[40]. The most significant lifestyle-related and modifiable
risk factors for elevated blood pressure are overweight sta-
tus, high intake of sodium, high intake of alcohol, and
physical inactivity. Also, a randomised controlled trial has
shown the beneficial effects of a lifestyle intervention
based on reduced sodium intake and increased intake of
fruits, vegetables, and low-fat dairy products [52]. Even
more dramatic effects could be achieved with a more
aggressive lifestyle intervention [53,54] than is considered
here.
Generally, in blood pressure group 0, the impact of the
application of the ACCG scenario was to reduce expected
costs at the same time as reducing the expected number of
life-years in comparison to the PCP scenario. This result is
likely to reflect the fact that the PCP scenario, with at least
some use of medication, is always treated by the model as
being more effective than monitoring (i.e., in BPG 0 active
surveillance is the only treatment option under the ACCG
scenario). In the majority of age- and gender-stratified
subgroups in BPG 1 and BPG 2, the ACCG scenario was
shown to be both cost-saving and more effective. Indeed,
these two groups are those for which, a priori, we expected
to see the greatest relative benefit from lifestyle counsel-
ling, either alone (in the case of BPG 1) or in combination
with medication for individuals at increased risk of CHD
(in the case of BPG 2). Generally, in BPG 3, increased
expected costs are associated with an increase in the
expected number of life-years. This mainly reflects the fact
that the ACCG scenario applies drug treatment to all indi-
viduals in BPG 3, whereas the PCP scenario treats only
some individuals in this group.
The cost-effectiveness plane with the results (aggregated  across subgroups) of the one-way sensitivity analyses Figure 4
The cost-effectiveness plane with the results (aggregated 
across subgroups) of the one-way sensitivity analyses.BMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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Other factors that are likely to have contributed greatly to
the results presented include both the manner in which
diagnosis is performed in the ACCG scenario and the fact
that inexpensive medications from within each pharma-
cological subgroup are used under the ACCG scenario.
The rational use of antihypertensive drugs can be pro-
moted by reference to both the severity of hypertension
and the costs of drug treatment [23,55]. The ACCG, for
instance, promotes the initiation of drug treatment using
a single pharmacological therapy [23]. In addition, for
most instances of combination treatment, one of the
drugs to be chosen is a thiazide diuretic [56].
Strengths of the study
This analysis is intended to be a pragmatic cost-effective-
ness analysis and firmly based on observed prior clinical
practice in Finland and on the operationalisation of the
Finnish evidence-based guidelines undertaken in this
study. Generalising the results of this study may, to some
extent, be justified in view of the broadly similar hyper-
tension-related disease burden in other settings and the
similarity of other evidence-based antihypertensive guide-
lines, such as the recently updated National Institute for
Clinical Excellence (NICE) guidelines [57].
The study presented here is based on an extraordinary set
of data sources, which include both exemplary national
registers with high coverage [58] and high-quality surveys
of population health (see [31] and [33]). The Hospital
Care Register, particularly as regards cardiovascular dis-
eases, has proved to be accurate [59]. The National Health
Insurance Scheme operates in all Finnish pharmacies, and
over 90% of reimbursements for the purchase of antihy-
pertensive drugs occur seamlessly at the point of sale.
In both the H2000 and MF surveys, the measurement of
BP was carried out according to the WHO recommenda-
tions. It is therefore credible that these datasets provide
classification of BP in line with measurements made in
standard clinical practice. In addition, both SBP and DBP
are used as part of the basis for BP classification, as recom-
mended by the ACCG.
Perhaps most importantly, this study offers rare insight
into the potential usefulness of developing clinical prac-
tice guidelines.
Limitations of the study
A number of caveats should be attached to all results and
discussion presented here, the following two being of
major importance. Firstly, that this is a model of limited
size, analytic capability, and adherence to economic eval-
uation guidelines. Secondly, because uncertainty concern-
ing the model inputs has not been fully incorporated, the
cost-effectiveness analyses reported here are best taken as
being indicative of the direction, rather than the exact
magnitude, of differences in costs and effects between the
two scenarios.
Further to this, pertinent evidence of adherence to either
the ACCG scenario or the PCP scenario had not been pub-
lished. The full-adherence assumption used in this study
deviates, somewhat, from what might be expected in
standard clinical practice. However, the practical effect of
this assumption is likely to be reduced by the fact that it
was used in the same manner in both scenarios. Indeed,
the financial costs associated with guideline development
and production in Finland are estimated to be minimal,
and, even with very low levels of adherence, their produc-
tion is likely to be economically viable in the long term.
The results of a sensitivity analysis concerning low levels
of adherence to the ACCG scenario in favour of continued
use of the PCP scenario are not presented here, as the
result is merely a linear scaling of the differences in the
costs and effects between the two scenarios. However, the
possibility remains that these results may be located
toward the upper end of the potential overall impact of
the ACCG scenario.
The ACCG itself is an evidence-based, advisory statement,
and treatment should always be tailored to the individual.
On the other hand, in the Markov model used here, the
ACCG scenario is implemented as if it were a prescriptive
scenario. Thus, the model does not fully incorporate the
subtleties and flexibilities of the ACCG. The result that the
ACCG scenario, in almost all age- and gender-stratified
BPG 0 subgroups, produces fewer life-years and costs than
the PCP scenario is also explained in part by the rigidity of
the model. In contrast to the observed use of antihyper-
tensive medications in prior clinical practice, in the ACCG
scenario no intervention is provided for BPG 0 (see Table
3). It is likely that the H2000 records on prior usage of
antihypertensive medications include some element of
overtreatment.
This study did not directly consider the cost of ACCG
development, nor the costs of ACCG implementation in
clinical practice [60]. This leads to an underestimate of the
costs of the ACCG scenario, but can be justified by refer-
ence to the fact that the ACCG scenario is not identically
equivalent to the whole of the evidence-based ACCG. The
costs included can be considered to consist mainly of the
costs borne by the health care sector. Value added tax was
subtracted from the recorded prices of the pharmaceuti-
cals. This could result in an underestimate of the cost bur-
den to the health care sector [61].
The number of treatments considered and the number of
health states representing alternative outcomes had to be
restricted in order to keep the Markov model simpleBMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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enough to be functional and able to populate the model.
Carrying out the analyses in 56 subgroups led to moder-
ately small sample sizes in some cases, but this was
deemed necessary for identifying any heterogeneity of the
impact on the subgroups. For example, due to lack of reli-
able or consistent data, this study does not incorporate
some health care costs and outcomes that potentially
could be associated with elevated blood pressure, such as
the costs and health-related effects of peripheral vascular
disease, renal disease, heart failure, diabetes, and lost
earnings [62]. This may well have resulted in an underes-
timate of the costs and effects associated with BP-related
disease but is also likely to result in an underestimate of
potential savings and benefits in outcome from BP reduc-
tion at the aggregated level.
At best, the estimates of BP effects on mortality and mor-
bidity should be treated as only indicative of the extent
and direction of the likely associations between BPG and
health status in terms of morbidity and mortality. The
estimates presented here are also subject to the assump-
tion of full benefit [12]. This assumes that the estimated
change in BP is achieved, that the effect of non-adherence
is negligible, that the change to (or inclusion in) a BP
group completely and linearly defines the risk of morbid-
ity and mortality, and that the amount of benefit does not
diminish within any age group. For a detailed presenta-
tion of other assumptions applied in this research, see
Additional file 8.
The estimates of the blood-pressure-reducing effects of
antihypertensive drugs and their combinations are to
some extent uncertain. At the time this CEA was under-
taken, data concerning the antihypertensive effect of ACE
inhibitors and beta-blockers in combination could not be
located. Combination treatment involving angiotensin II
subtype 1 receptor antagonists had been studied only for
combinations involving diuretics. Research on three-drug
combination treatment is especially sparse [57]. Drugs
with different pharmacological mechanisms – i.e., differ-
ent classes of antihypertensive drugs – seem to intensify
one another's effects.
The potential effect of substitution with generic equiva-
lents, for which legislation has been in place in Finland
since 1 April 2003, was not incorporated into the base
case analysis. Equivalence, in terms of side effects, of the
pharmacological therapies was assumed in the absence of
strong evidence to the contrary. Therefore, the impact of
potential side effects on antihypertensive care (discontin-
uation of treatment or regimen change and costs associ-
ated therewith) or on individuals (HRQL effects) is
assumed to be the same and is omitted from considera-
tion.
Probabilistic sensitivity analysis was not carried out,
partly on account of the assumed robust nature of the
datasets used [63]. In addition, the complexity of the
Markov model did not allow easy application of probabi-
listic sensitivity analysis. One-way sensitivity analyses
showed that exaggerated increases in the cost of lifestyle
counselling was the only variant investigated that changed
the aggregated result from that of the ACCG scenario
being dominant to that of it being both more costly and
more effective.
Conclusion
The aggregated results showed that the ACCG scenario is
less costly and produces more life-years than the PCP sce-
nario. However, there was heterogeneity in the results
from the 56 subgroups analysed – i.e., ranging from losses
in life-years and increased costs in one subgroup to gains
in life-years and reduced costs in others. The most consist-
ently positive effects of the ACCG scenario (decreased
costs and an increased number of life-years) were
observed for males with moderately elevated blood pres-
sure – that is, for those in BPGs 1 and 2. On the other
hand, generally, the effect of the application of the ACCG
scenario in BPG 0 was to reduce costs at the same time as
the number of life-years.
Although aggregated results alone can be of value to deci-
sion-making entities, here they are accompanied by more
detailed information from subgroup-specific results. This
subgroup-specific information is of potential importance
to decision-making entities, too. The aggregated ICER
results presented here assume that individuals and groups
are treated equally in keeping with ex ante equity concerns
– i.e., that, as is usual in cost-effectiveness analyses, equity
is restricted to a specific form of 'equitable efficiency' [64].
'Equitably efficient' usually refers to a situation where
reductions in life-years for one group are given an equal
and opposite weight to gains in life-years in another. For
example, here we assume that the relevant objective func-
tion is the maximisation of a proxy for health – life-years
– and that each life-year is valued equally, irrespective of
which group loses or gains it. However, generally, society-
level decision-makers' objectives include separate consid-
erations of efficiency and equity. Therefore, whether the
ACCG scenario represents an improvement in societal
welfare and thus is preferable to the PCP scenario is a
value judgement [65], and the applicability of the consid-
eration of equity employed here is left for decision-makers
to judge.
If the estimated trade-offs between the subgroups in terms
of outcomes and costs are acceptable to decision-makers,
then widespread implementation of the ACCG scenario is
expected to reduce overall costs and be accompanied by
positive outcomes overall.BMC Health Services Research 2007, 7:172 http://www.biomedcentral.com/1472-6963/7/172
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ACCG = the 2002 Antihypertensive Current Care Guide-
line [23]
ACE = angiotensin-converting enzyme
ATC = Anatomical Therapeutic Chemical classification
system
BP = blood pressure (indirect measurement using an
external measuring device)
BPG = blood pressure group (see Table 2)
C03EA = hydrochlorothiazide or trichlormethiazide and
potassium-sparing agents
C07A = beta-blocking agents
C07B = combination of metoprolol or bisoprolol and thi-
azides
C07F = atenolol or metoprolol and, e.g., calcium channel
blockers
C08 = calcium channel blockers
C09A = ACE inhibitors
C09BA = combination of ACE inhibitors and diuretics
C09BB = combination of ACE inhibitors and calcium
channel blockers
C09C = angiotensin II subtype 1 receptor antagonists
C09D = combination of angiotensin II subtype 1 receptor
antagonists and diuretics
CEA = cost-effectiveness analysis (see Additional file 1,
Table 2 for further details)
CHD = coronary heart disease
CVE = cerebrovascular event
DBP = diastolic blood pressure
H2000 = Health 2000 health examination/interview sur-
vey (2000–2001)
HRQL = health-related quality of life
ICER = incremental cost-effectiveness ratio (see Addi-
tional file 1, Table 2 for further details)
LSC = lifestyle counselling (only used in the ACCG sce-
nario)
MF = Mini-Finland health examination/interview survey
(1978–1980)
PCP = prior clinical practice (clinical practice prior to the
publication of the ACCG)
SBP = systolic blood pressure
SII = Finnish Social Insurance Institution (KELA)
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